Status:
COMPLETED
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to investigate the percentage of patients reaching the treatment target on blood glucose control after treatment with either hum...
Eligibility Criteria
Inclusion
- After the investigator has taken the decision to use human insulin or insulin analogues to treat the subject, any type 2 diabetic previously inadequately controlled with two or more OADs is eligible for the study
- The selection of the subjects will be at the discretion of the individual investigator
Exclusion
- Known or suspected allergy to trial product(s) or related products
- Subjects who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit
- Subjects who previously enrolled in this study
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
- The receipt of any investigational product within 3 months prior to this trial
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
4847 Patients enrolled
Trial Details
Trial ID
NCT00806936
Start Date
December 1 2008
End Date
December 1 2009
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100004